{
    "clinical_study": {
        "@rank": "79074", 
        "arm_group": {
            "arm_group_label": "Pioglitazone/glimepiride", 
            "description": "Pioglitazone/glimepiride 15 mg/1 mg, orally once daily before or after breakfast"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and efficacy of long-term use of\n      pioglitazone/glimepiride combination tablets (Sonias Combination Tablets LD) in patients\n      with type 2 diabetes mellitus who respond poorly to pioglitazone hydrochloride monotherapy\n      (pioglitazone at 15 mg/day) in the routine clinical setting."
        }, 
        "brief_title": "Pioglitazone/Glimepiride (Sonias) Combination Tablets Special Drug Use Surveillance Survey in Patients With Type 2 Diabetes Mellitus Who Respond Poorly to Pioglitazone", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a special drug use surveillance on long-term use of pioglitazone/glimepiride\n      combination tablets (Sonias Combination Tablets LD) designed to investigate the frequency of\n      adverse drug reactions in patients with type 2 diabetes mellitus who respond poorly to\n      pioglitazone hydrochloride monotherapy (pioglitazone at 15 mg/day).\n\n      The usual adult dosage is one tablet (15 mg/1 mg of pioglitazone/glimepiride) administered\n      orally once daily before or after breakfast."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with type 2 diabetes mellitus for whom treatment with pioglitazone\n             hydrochloride monotherapy (pioglitazone at 15 mg/day) is considered inefficacious as\n             per physician's assessment and for whom long-term treatment with\n             pioglitazone/glimepiride combination tablets is considered necessary\n\n        Exclusion Criteria:\n\n          -  (1) Patients with cardiac failure or a history of cardiac failure (2) Patients with\n             serious hepatic or renal impairment (3) Patients with severe ketosis, diabetic coma\n             or precoma, or type 1 diabetes mellitus (4) Patients with severe infection, severe\n             trauma, or pre- and post-operative patients (5) Patients with gastrointestinal\n             disorders such as diarrhea and vomiting (6) Pregnant or potentially pregnant women\n             (7) Patients with a history of hypersensitivity to the ingredients in Sonias\n             Combination Tablets or sulfonamides"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Type 2 diabetes"
            }
        }, 
        "enrollment": {
            "#text": "294", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02098746", 
            "org_study_id": "097-012"
        }, 
        "intervention": {
            "arm_group_label": "Pioglitazone/glimepiride", 
            "description": "Pioglitazone/glimepiride combination tablets", 
            "intervention_name": "Pioglitazone/glimepiride", 
            "intervention_type": "Drug", 
            "other_name": "Sonias combination tablets LD"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Glimepiride", 
                "Pioglitazone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Pharmacological therapy", 
        "lastchanged_date": "March 25, 2014", 
        "number_of_groups": "1", 
        "official_title": "Sonias Combination Tablets LD Special Drug Use Surveillance Survey in Patients With Type 2 Diabetes Mellitus Who Respond Poorly to Pioglitazone", 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Postmarketing Group Manager", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Frequency, seriousness, and time to onset of adverse drug reactions tabulated by each symptom. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug. Among these, events which are considered possibly associated with a medicinal product are defined as adverse drug reactions.", 
            "measure": "Frequency of adverse drug reactions", 
            "safety_issue": "Yes", 
            "time_frame": "For 12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02098746"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Tabulation of HbA1c values and the changes from baseline at each test time point (test value at each test time point after baseline - test value at baseline)", 
                "measure": "Change from baseline in glycosylated hemoglobin (HbA1c)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and month 12"
            }, 
            {
                "description": "Tabulation of fasting blood glucose level and the changes from baseline at each test time point (test value at each test time point after baseline - test value at baseline)", 
                "measure": "Change from baseline in fasting blood glucose level", 
                "safety_issue": "No", 
                "time_frame": "Baseline and month 12"
            }, 
            {
                "description": "Tabulation of fasting insulin level and the changes from baseline at each test time point (test value at each test time point after baseline - test value at baseline)", 
                "measure": "Change from baseline in fasting insulin level", 
                "safety_issue": "No", 
                "time_frame": "Baseline and month 12"
            }
        ], 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}